Continuous therapy in HHV-8 negative Multicentric Castleman Disease and prolonged progression-free survival,Journal of Hematology & Oncology

当前位置： X-MOL 学术 › J. Hematol. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Continuous therapy in HHV-8 negative Multicentric Castleman Disease and prolonged progression-free survival
Journal of Hematology & Oncology ( IF 29.5 ) Pub Date : 2024-08-06 , DOI: 10.1186/s13045-024-01588-9
Yi Liu _{1,

2,

3} , Xuejiao Yin _{1,

2,

3} , Shengnan Ding _{1,

2} , Jiaying Ge _{1,

2} , Liya Ma _{1,

2} , Min Yang _{1,

2} , Xuxia Luo ₁ , Chengli Zhong ₁ , Sishi Fang ₁ , Qiumei Yao _{1,

2} , Li Zhu _{1,

2} , Wenjuan Yu _{1,

2} , Liping Mao _{1,

2} , Juying Wei _{1,

2} , Xingnong Ye _{1,

2} , De Zhou _{1,

2} , Hongyan Tong _{1,

2,

3,

4} , Haitao Meng _{1,

2,

3,

4} , Jie Jin _{1,

2,

3,

4} , Liangshun You _{1,

2,

3,

4}

Affiliation

The optimal treatment endpoints and duration of continuous therapy for multicentric Castleman disease (MCD) remain controversial. We retrospectively analyzed data from 123 patients with Human Herpesvirus (HHV)-8 negative MCD. We demonstrated that continuous therapy significantly enhanced progression-free survival (PFS) in patients who achieved an optimal response after initial treatment. These findings underscore the critical role of continuous therapy in HHV-8 negative MCD. Further studies with larger cohorts are required to validate these findings.

中文翻译：

HHV-8 阴性多中心 Castleman 病的持续治疗和延长的无进展生存期

多中心 Castleman 病（MCD）的最佳治疗终点和持续治疗持续时间仍存在争议。我们回顾性分析了 123 例人类疱疹病毒（HHV）-8 阴性 MCD 患者的数据。我们证明，持续治疗显着提高了初始治疗后达到最佳反应的患者的无进展生存期（PFS）。这些发现强调了持续治疗在 HHV-8 阴性 MCD 中的关键作用。需要对更大队列进行进一步研究来验证这些发现。

更新日期：2024-08-06

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南